NCT06947928View on ClinicalTrials.gov

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

December 30, 2032

Conditions
Advanced Or Metastatic Merkel Cell Carcinoma
Interventions
DRUG

IFx-Hu2.0

"Therapeutic Classification:~• Innate immune agonist~Route of Administration:~• Intralesional"

DRUG

Placebo

"Route of Administration:~• Intralesional"

DRUG

Pembrolizumab

"Therapeutic Classification:~• Immunotherapy (Immune checkpoint inhibitor)~Route of administration:~• Intravenous (IV) infusion"

Trial Locations (8)

23298

RECRUITING

Virginia Commonwealth University - Massey Cancer Center, Richmond

27834

RECRUITING

East Carolina University, Greenville

90033

RECRUITING

USC Norris Comprehensive Cancer Center, Los Angeles

94143

RECRUITING

University of California San Francisco - Helen Diller Family Comprehensive Cancer Center, San Francisco

94304

RECRUITING

Stanford Health Care - Skin Cancer Program, Palo Alto

98109

RECRUITING

Fred Hutchinson Cancer Research Center, Seattle

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

07960

RECRUITING

Atlantic Health System, Morristown

All Listed Sponsors
lead

TuHURA Biosciences, Inc.

INDUSTRY